C9307 HCPCS code: Injection, linvoseltamab-gcpt, 1 mg
C9307 is the HCPCS Level II code for injection, linvoseltamab-gcpt, 1 mg. CMS terminated C9307 on 2026-03-31; do not bill it for later dates of service. Its Medicare coverage code is D (Special coverage instructions apply): Medicare covers it when its national or local coverage criteria are met.
Code details
| Field | Value |
|---|---|
| Section | C codes — Outpatient PPS (hospital outpatient temporary codes) |
| Coverage code | D — Special coverage instructions apply |
| Pricing indicator | 53 |
| BETOS category | O1E — Other drugs |
| Added | 2026-01-01 |
| Last action effective | 2026-04-01 |
| Terminated | 2026-03-31 |
What changed for C9307
- January 2026: Code appears in this HCPCS release
- 2026-01-01: C9307 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code C9307?
C9307 is the HCPCS Level II code for injection, linvoseltamab-gcpt, 1 mg. Short descriptor: "Inj linvoseltamab-gcpt 1 mg".
Does Medicare cover C9307?
Coverage code D — Special coverage instructions apply. Medicare covers it when its national or local coverage criteria are met.
Related C93 codes
- C9300 — Injection, indigotindisulfonate sodium, 1 mg
- C9301 — Obecabtagene autoleucel, up to 400 million cd19 car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
- C9302 — Injection, zanidatamab-hrii, 2 mg
- C9303 — Injection, zolbetuximab-clzb, 1 mg
- C9304 — Injection, marstacimab-hncq, 0.5 mg
- C9305 — Injection, nipocalimab-aahu, 3 mg
- C9306 — Injection, telisotuzumab vedotin-tllv, 1 mg
- C9308 — Injection, carboplatin (avyxa), 1 mg
- C9309 — Injection, onasemnogene abeparvovec-brve, per treatment
- C9310 — Injection, leucovorin calcium (avyxa), 1 mg
- C9311 — Injection, eplontersen, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)
- C9312 — Injection, trabectedin (apotex), not therapeutically equivalent to j9362, 0.01 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under C9307
- Watch C9307 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for C9307
Sources: CMS HCPCS Level II release October 2026; CMS DMEPOS fee schedule; CMS NCCI MUE tables; CMS Medicare utilization (physician and DME supplier files); CMS Medicare Coverage Database articles. Fees are Medicare allowables, not commercial rates. Not billing or legal advice.